Anti pr

Manufactured by Agilent Technologies

Sourced in United States

The Anti-PR is a specialized lab equipment designed for performing immunoprecipitation experiments. It features a high-affinity anti-protein A resin that can effectively capture and isolate target proteins from complex biological samples. The core function of the Anti-PR is to enable researchers to purify and analyze specific proteins of interest.

Automatically generated - may contain errors

Lab products found in correlation

Akt 4691, by Cell Signaling Technology (1 mentions) Ecl reagent, by Advansta (1 mentions) Polyvinylidene difluoride membrane, by Merck Group (1 mentions) Pakt 4060, by Cell Signaling Technology (1 mentions) Re blot plus mild solution, by Merck Group (1 mentions) Anti actin, by Santa Cruz Biotechnology (1 mentions) Pbs t, by Merck Group (1 mentions) Anti ki67, by Agilent Technologies (1 mentions) Benchmark xt, by Roche (1 mentions) Anti her2, by Agilent Technologies (1 mentions) Anti ck5 6, by Agilent Technologies (1 mentions) Anti pcna, by Agilent Technologies (1 mentions) Anti er, by Abcam (1 mentions) Rat anti brdu, by Abcam (1 mentions) Rabbit anti zo 1, by Thermo Fisher Scientific (1 mentions) Cryostat, by Leica (1 mentions) Mouse anti gm130, by BD (1 mentions) Anti sma, by Merck Group (1 mentions) Anti erα, by Agilent Technologies (1 mentions) Anti fscn1, by Santa Cruz Biotechnology (1 mentions)

5 protocols using anti pr

Western Blot Analysis of PTEN, AKT, PR, and ER

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tissue and cell line samples containing 15 μg of protein were applied to SDS-PAGE 8–12% Bis-tris gel. The separated proteins were transferred onto a polyvinylidene difluoride membrane (Millipore Corp. Burlington, MA USA). Membranes were blocked overnight with 0.5% casein (wt/vol) in Phosphate Buffered Saline with 0.1% Tween 20 (vol/vol) (PBS-T) (Sigma-Aldrich. St. Louis, MO USA) and probed with anti-PTEN (9188, Cell Signaling), pAKT (4060, Cell Signaling), AKT (4691, Cell Signaling), anti-PR (DAKO Corp. Capinteria, CA USA), or anti-ERα (DAKO Corp.) antibodies. Immunoreactivity was visualized by incubation with a horseradish peroxidase-linked secondary antibody and treatment with ECL reagents (Advansta. Menlo Park, CA USA). Membranes were stripped and re-probed for each antibody using Re-blot Plus Mild Solution (2502, Millipore). To control for loading, the membrane was stripped and probed with anti-actin (Santa Cruz Biotechnology Inc. Santa Cruz, CA USA) and developed again.

Fedorko A.M., Kim T.H., Broaddus R., Schmandt R., Chandramouli G.V., Kim H.I., Jeong J.W, & Risinger J.I. (2020). An immune competent orthotopic model of endometrial cancer with metastasis. Heliyon, 6(5), e04075.

+ Open protocol

+ Expand

Molecular Subtyping of Salivary Carcinomas

Check if the same lab product or an alternative is used in the 5 most similar protocols

A total of 22 out of 29 SeCs were classified into 5 molecular subtypes in a similar way to breast cancer, as described in our previous study (luminal 1, luminal 2, HER2, all-negative, and core basal) (Table S2) [24 (link)]. The remaining 7 cases had no available tissue for IHC study. An automated immunostainer (Ventana BenchMark XT, Tucson, AZ, USA) was used to perform the IHC for anti-HER2 (Dako, Carpinteria, CA, USA), antiandrogen receptor (anti-AR; Thermo Scientific, Carlsbad, CA, USA), anti-ER (Dako), anti-PR (Dako), anti-CK5/6 (Dako), and anti-Ki67 (Dako) antibodies. The interpretation of HER2 IHC results was based on the 2013 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines [34 (link)]. Finally, scores of 2+ and 3+ were considered positive for HER2. For hormone receptors (HRs), including AR, ER, and PR, it was considered positive when ≥1% of the tumor cell nuclei were stained. CK5/6 was scored when ≥50% of the tumor cells were strongly immunoreactive [24 (link)].

Na H.Y., Park J.H., Shin S.A., Lee S., Lee H., Chae H., Choung H., Kim N., Chung J.H, & Kim J.E. (2021). Targeted Sequencing Revealed Distinct Mutational Profiles of Ocular and Extraocular Sebaceous Carcinomas. Cancers, 13(19), 4810.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Hydrogel Cultures

Check if the same lab product or an alternative is used in the 5 most similar protocols

Parallel gel samples were processed for frozen and paraffin embedded sections. Following formalin fixation to obtain frozen sections, gels were washed with PBS and placed in OCT (TissueTek) with 30% sucrose at 4°C overnight. Gels were then flash frozen on liquid N₂ and 8–10 μm sections were prepared using a cryostat (Leica). Staining of gels was carried out with the following antibodies and concentrations: 1:100 mouse anti-GM130 (BD Biosciences), 1:100 rabbit anti-laminin-5 (Abcam), 1:200 rabbit anti-ZO1 (Invitrogen), and TUNEL stain (Roche kit). Paraffin-embedded gel sections were stained with 1:200 rat anti-BrdU (Abcam). Paraffin tissue sections were prepared by the Harvard Medical School histology core facility and stained with 1:100 anti-ER (Abcam), 1:400 anti-PR (Dako), 1:100 anti-PCNA (Dako) and TUNEL (Roche). Stained sections were imaged at 40X using a Zeiss Imager and cells from at least 5 representative fields were quantified per animal.

Brock A., Krause S., Li H., Kowalski M., Goldberg M.S., Collins J.J, & Ingber D.E. (2014). Prevention of mammary tumor progression by silencing HoxA1 via intraductal injection of nanoparticle-formulated siRNA. Science translational medicine, 6(217), 217ra2.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Molecular Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

The antibodies used in this study were anti-ERα (#IR151, Dako), anti-FSCN1 (#SC-56531, Santa Cruz Biotechnology), anti-HMB-45 (#SC-59305, Santa Cruz Biotechnology), anti ID1 (#SC-488, Santa Cruz Biotechnology), anti-PR (#IR168, Dako), anti-phospho-Ser235-236 S6 ribosomal protein (anti-pS6; clone 91B2, Cell Signaling Technology), anti-SMA (#A2547, Sigma-Aldrich), and anti-SOX9 (#AB5535, Millipore).

Nuñez O., Román A., Johnson S.R., Inoue Y., Hirose M., Casanova Á., de Garibay G.R., Herranz C., Bueno-Moreno G., Boni J., Mateo F., Petit A., Climent F., Soler T., Vidal A., Sánchez-Mut J.V., Esteller M., López J.I., García N., Gumà A., Ortega R., Plà M.J., Campos M., Ansótegui E., Molina-Molina M., Valenzuela C., Ussetti P., Laporta R., Ancochea J., Xaubet A., Pollán M, & Pujana M.A. (2016). Study of breast cancer incidence in patients of lymphangioleiomyomatosis. Breast Cancer Research and Treatment, 156, 195-201.

+ Open protocol

+ Expand

Steroid Receptor Signaling Pathway Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Methyltrienolone (R1881), 17β-estradiol (E2), and androstenedione (AD) were obtained from Sigma (St. Louis, MO). Anastrazole (Arimidex, Ana) was obtained from AstraZeneca (London, UK), and bicalutamide (Casodex^®, Cx) was purchased from LKT Laboratories Inc. (St. Paul, MN). Abiraterone acetate was a kind gift from Janssen Pharmaceuticals (Beerse, Belgium). Antibodies used for immunoblotting were anti-GAPDH from Santa Cruz Biotechnology (Santa Cruz, CA), anti-ERα 6F11 from Vector Laboratories Inc. (Burlingame, CA), anti-PR from DAKO (Carpinteria, CA), anti- total and phosphorylated IRS-1, HER2, IGF-1R, AKT, and MAPK from Cell Signaling Technology (Beverly, MA), anti-AR clone 441 from Santa Cruz Biotechnology, and anti-aromatase (CYP19) from Serotec (Oxford, UK). MTT (Thiazoyl blue tetrazolium bromide) was obtained from Sigma.

Rechoum Y., Rovito D., Iacopetta D., Barone I., Andò S., Weigel N.L., O’Malley B.W., Brown P.H, & Fuqua S.A. (2014). AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. Breast cancer research and treatment, 147(3), 473-485.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!